Minerva Neurosciences to Present at Upcoming Investor Conferences in June

Minerva Neurosciences to Present at Upcoming Investor Conferences in June 24 KB

WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases and disorders, today announced that it will participate in the following upcoming investor conferences:

Event:	Jefferies 2015 Global Healthcare Conference
Date / Time:	Thursday, June 4, 2015 at 11:00 AM (EDT)
Location:	New York, NY

Event:	JMP Securities Life Sciences Conference 2015
Date / Time:	Tuesday, June 23, 2015 at 3:00 PM (EDT)
Location:	The St. Regis New York, New York, NY

Live audio webcasts will be available online from the investor relations section of the company’s website at http://ir.minervaneurosciences.com. A replay of the presentation will be posted on the Minerva website approximately one hour after the events and will be available for the following 30 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva is developing proprietary compounds, including its lead program MIN-101 in development for the treatment of schizophrenia, MIN-202 (JNJ-922) in development for primary and comorbid insomnia, MIN-117 in development for the treatment of major depressive disorder and MIN-301 in development for the treatment of Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market where it trades under the symbol “NERV”. For more information, please visit:
www.minervaneurosciences.com/.

CONTACT: Media Contact:

         Bill Berry

         Berry & Company Public Relations

         212-253-8881

         bberry@berrypr.com



         Investor Contact:

         Stephanie Ascher

         Stern Investor Relations

         212-362-1200

         stephanie@sternir.com

Source: Minerva Neurosciences, Inc

News Provided by Acquire Media